4 ms·
The short summary of what this paper describes is an increase in GBS specific to the Johnson & Johnson vaccine (Ad.26.COV2.S), with no significant change for re
by neogodless 5y ago
The short summary of what this paper describes is an increase in GBS specific to the Johnson & Johnson vaccine (Ad.26.COV2.S), with no significant change for recipients of mRNA vaccines.
> The incidence of GBS in the 21 days after Ad.26.COV2.S was 34.6 per 100,000 person-years, which was substantially greater than the expected background rate of 1-2 per 100,000 person-years.